Drug resistant integrase mutants cause aberrant HIV integrations.
BACKGROUND
HIV-1 integrase is the target for three FDA-approved drugs, raltegravir, elvitegravir, and dolutegravir. All three drugs bind at the active site of integrase and block the strand transfer step of integration. We previously showed that sub-optimal doses of the anti-HIV drug raltegravir can cause aberrant HIV integrations that are accompanied by a variety of deletions, duplications, insertions and inversions of the adjacent host sequences.


RESULTS
We show here that a second drug, elvitegravir, also causes similar aberrant integrations. More importantly, we show that at least two of the three clinically relevant drug resistant integrase mutants we tested, N155H and G140S/Q148H, which reduce the enzymatic activity of integrase, can cause the same sorts of aberrant integrations, even in the absence of drugs. In addition, these drug resistant mutants have an elevated IC50for anti-integrase drugs, and concentrations of the drugs that would be optimal against the WT virus are suboptimal for the mutants.


CONCLUSIONS
We previously showed that suboptimal doses of a drug that binds to the HIV enzyme integrase and blocks the integration of a DNA copy of the viral genome into host DNA can cause aberrant integrations that involve rearrangements of the host DNA. We show here that suboptimal doses of a second anti-integrase drug can cause similar aberrant integrations. We also show that drug-resistance mutations in HIV integrase can also cause aberrant integrations, even in the absence of an anti-integrase drug. HIV DNA integrations in the oncogenes BACH2 and MKL2 that do not involve rearrangements of the viral or host DNA can stimulate the proliferation of infected cells. Based on what is known about the association of DNA rearrangements and the activation of oncogenes in human tumors, it is possible that some of the deletions, duplications, insertions, and inversions of the host DNA that accompany aberrant HIV DNA integrations could increase the chances that HIV integrations could lead to the development of a tumor.
HIV Dynamics and Replication Program, Vector Design and Replication Section, National Cancer Institute-Frederick, 1050 Boyles Street, Bldg. 539, Room 130A, Frederick, MD, 21702, USA.|Department of Pathology, Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA.
Janani
J
Varadarajan
HIV Dynamics and Replication Program, Vector Design and Replication Section, National Cancer Institute-Frederick, 1050 Boyles Street, Bldg. 539, Room 130A, Frederick, MD, 21702, USA.
Mary Jane
MJ
McWilliams
Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Bryan T
BT
Mott
Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA.
Craig J
CJ
Thomas
HIV Dynamics and Replication Program, Vector Design and Replication Section, National Cancer Institute-Frederick, 1050 Boyles Street, Bldg. 539, Room 130A, Frederick, MD, 21702, USA.
Steven J
SJ
Smith
HIV Dynamics and Replication Program, Vector Design and Replication Section, National Cancer Institute-Frederick, 1050 Boyles Street, Bldg. 539, Room 130A, Frederick, MD, 21702, USA. hughesst@mail.nih.gov.
Stephen H
SH
Hughes
Aberrant integration; Drug resistance; Elvitegravir; HIV
ACS Chem Biol. 2016 Apr 15;11(4):1074-81
26808478
EMBO J. 2006 Mar 22;25(6):1295-304
16482214
J Acquir Immune Defic Syndr. 2003 Jul 1;33(3):308-20
12843741
Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10380-5
15240889
Chem Biol Drug Des. 2012 Feb;79(2):157-65
22107736
Curr Opin Infect Dis. 2013 Feb;26(1):43-9
23242340
Curr Opin Struct Biol. 2011 Apr;21(2):249-56
21277766
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):20057-62
21030679
ACS Chem Biol. 2013 Jan 18;8(1):209-17
23075516
Nat Rev Cancer. 2011 Feb;11(2):96-110
21258395
Mutat Res. 2013 Mar-Apr;743-744:97-110
23195997
J Virol. 2006 Oct;80(20):10281-4
17005708
Antimicrob Agents Chemother. 2013 Jun;57(6):2654-63
23529738
J Virol. 2008 Nov;82(22):11480-3
18768972
J Virol. 2008 Jan;82(2):719-27
17989171
Biochemistry. 2008 Sep 9;47(36):9345-54
18702518
Cold Spring Harb Perspect Med. 2012 Apr;2(4):a007161
22474613
Cancer Cell. 2013 Sep 9;24(3):282-4
24029225
Proc Natl Acad Sci U S A. 1989 Apr;86(8):2525-9
2539592
Histopathology. 2013 May;62(6):925-30
23672313
Antimicrob Agents Chemother. 2011 Nov;55(11):5127-33
21876054
PLoS Pathog. 2009 Jan;5(1):e1000259
19132083
J Virol. 2008 Jan;82(1):503-12
17959663
J Acquir Immune Defic Syndr. 2010 Oct;55(2):148-55
20634701
Oncogene. 2012 Aug 30;31(35):3913-23
22139079
J Antimicrob Chemother. 2014 Sep;69(9):2412-9
24860155
J Virol. 2006 Jan;80(1):451-9
16352569
BMC Mol Biol. 2009 Jan 21;10:2
19159451
Science. 2014 Aug 1;345(6196):570-3
25011556
Mol Pharmacol. 2011 Oct;80(4):565-72
21719464
J Med Chem. 2014 Feb 27;57(4):1573-82
24471816
Crit Rev Eukaryot Gene Expr. 2011;21(4):323-36
22181702
Genes Chromosomes Cancer. 2011 Apr;50(4):207-16
21319257
Nucleic Acids Res. 2009 Mar;37(4):1193-201
19129221
Bioorg Med Chem Lett. 2012 Dec 15;22(24):7309-13
23149229
J Virol. 2010 Oct;84(19):9864-78
20660205
Science. 2014 Jul 11;345(6193):179-83
24968937
Clin Infect Dis. 2009 Apr 1;48(7):931-9
19231980
Proc Natl Acad Sci U S A. 2013 Sep 3;110(36):14747-52
23959861
Nature. 2010 Mar 11;464(7286):232-6
20118915